Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an ...

Canada has an opportunity to prevent sustained Clade I mpox transmission, but only if decisive action is taken now.

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army ...

SAN FRANCISCO — Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral that was stopped early based on a futility analysis ...

Our flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the ...

After a review of evidence, the UK Health Security Agency (HSA) said today that it no longer classifies clade 1a and 1b mpox ...

SIGA Technologies (SIGA) announced the appointment of Retired United States Army General John “Jack” Keane to its Board of Directors, effective ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...